CLSN Celsion Corp

Celsion Corp is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies.

$2.04
As of 03/03/2021     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Micro cap
Health Care
Biotechnology
USA
USA
08/01/2001
37,417,716
34,366,894
$76,332,141
0.00%
SEC Edgar Online
10-Q
10-K
15117N503
US15117N5032
BF43JD5

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-3.54
3.95
152.66
-115.62%
-4,314.83%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy